Share on StockTwits

HeartWare International (NASDAQ:HTWR) Director Robert Bain Thomas sold 1,000 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $81.97, for a total value of $81,970.00. Following the transaction, the director now directly owns 2,260 shares of the company’s stock, valued at approximately $185,252. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of HeartWare International (NASDAQ:HTWR) traded down 0.10% on Thursday, hitting $80.37. The stock had a trading volume of 21,604 shares. HeartWare International has a one year low of $69.31 and a one year high of $105.84. The stock has a 50-day moving average of $85.3 and a 200-day moving average of $90.29. The company’s market cap is $1.367 billion.

HeartWare International (NASDAQ:HTWR) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. Analysts expect that HeartWare International will post $-2.20 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of HeartWare International in a research note on Friday, August 1st. They now have a $125.00 price target on the stock, down previously from $128.00. Separately, analysts at Leerink Swann cut their price target on shares of HeartWare International from $120.00 to $105.00 in a research note on Friday, August 1st. Finally, analysts at Zacks upgraded shares of HeartWare International from a “neutral” rating to an “outperform” rating in a research note on Friday, August 1st. They now have a $105.70 price target on the stock. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $108.97.

Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.

Receive News & Ratings for HeartWare International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.